Výsledky vyhledávání - "Pirow J, Bekker"

Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget’s Disease1

Autor: Pirow J. Bekker, Thomas L. Clemens, Rachelle Eusebio, Frederick R. Singer

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 83:1906-1910

Thirteen patients with severe Paget’s disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg oral risedronate daily for 8 weeks. Patients were followed for 16 weeks without treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72dfba7d7322c5cd878039cd8eccde74
https://doi.org/10.1210/jcem.83.6.4871

Zobrazit plný text záznamu

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study

Autor: Paul D. Miller, L. E. Mallette, C Conrad Johnston, Ethel S. Siris, Joseph R. Tucci, Pirow J. Bekker, Jacques P. Brown, Chines Arkadi Aaron, Michael R. McClung, Roy D. Altman, Rachelle Eusebio, Will G. Ryan, Robert Lang, Frederick R. Singer

Publikováno v: Journal of Bone and Mineral Research. 13:1032-1038

An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50295767c11f94b9ee09ff9d886ce032
https://doi.org/10.1359/jbmr.1998.13.6.1032

Zobrazit plný text záznamu

Risedronate Increases Bone Mass in an Early Postmenopausal Population: Two Years of Treatment Plus One Year of Follow-Up1

Autor: Lene S. Mortensen, C. Conrad Johnston, Joseph Digennaro, Pirow J. Bekker, Peder Charles

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 83:396-402

This double-blind, placebo-controlled study was undertaken to determine 1) the efficacy of oral risedronate for prevention of bone loss in healthy, early postmenopausal patients with normal bone mass, 2) the effect on bone mass when treatment was sto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52bdaa9a0ed87c67e958705490087b36
https://doi.org/10.1210/jcem.83.2.4586

Zobrazit plný text záznamu

[Untitled]

Autor: Karen A. Pallone, John D. Nesbitt, Lisa E. Dunlap, Marian E. Clay, Rachelle Eusebio, Pirow J. Bekker, Darrell A. Russell, David Y. Mitchell

Publikováno v: Pharmaceutical Research. 15:228-232

Purpose. Two studies were conducted to compare the absorption of risedronate administered as a solution to three different gastrointestinal sites (study A) and to determine the extent of absorption of risedronate solution administered by rapid and sl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7671a72e28f6d46709fabbe8d509d104
https://doi.org/10.1023/a:1011910517200

Zobrazit plný text záznamu

A pharmaco-scintigraphy study of riboflavin 5′-phosphate sodium capsules (1 vs. 4)

Autor: Richard John Dansereau, Pirow J. Bekker, Bruce R. Line, Raymond N. Dansereau, Daniel P. Healy

Publikováno v: International Journal of Pharmaceutics. 153:159-166

The comparative in-vivo disintegration, gastric emptying and bioavailability of 41 mg radiolabeled riboflavin 5′-phosphate sodium capsules administered as a single hard gelatin capsule or as four capsules was evaluated in human subjects. A total of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce0162d278828789738bfe2e7840d5f9
https://doi.org/10.1016/s0378-5173(97)00090-2

Zobrazit plný text záznamu

Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women

Autor: Philip T. Leese, Donna Holloway, Steven W. Martin, Marc R. Gastonguay, Pirow J. Bekker, Mark C. Peterson, Matthew L. Zierhut, Paolo Vicini

Publikováno v: Journal of pharmacokinetics and pharmacodynamics. 35(4)

Osteoporosis is a metabolic bone disease resulting from increased bone resorption and characterized by low bone mass that leads to increased bone fragility and risk of fracture, particularly of the hip, spine and wrist. Bone resorption is dependent o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e65611315ae37f6fdfd8199872c06c1
https://pubmed.ncbi.nlm.nih.gov/18633695

Zobrazit plný text záznamu

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004

Autor: Pirow J, Bekker, Donna L, Holloway, Amy S, Rasmussen, Robyn, Murphy, Steven W, Martin, Philip T, Leese, Gregory B, Holmes, Colin R, Dunstan, Alex M, DePaoli

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 20(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6a5cb3497d690d64c22acae651422614
https://pubmed.ncbi.nlm.nih.gov/16432953

Zobrazit plný text záznamu

Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations

Autor: Pirow J. Bekker, P. E. Blackshaw, R. M. Vincent, Clive G. Wilson, K D Juhlin, Robin C. Spiller, Malcolm Frier, Richard John Dansereau, Alan C. Perkins

Publikováno v: International journal of pharmaceutics. 186(2)

Risedronate sodium is an orally active antiresorptive agent and a member of the pyridinyl class of bisphosphonates. It has been approved for the treatment of Paget's disease of the bone and is under development as a chronic therapy for the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1067d9956bc0b8d34c7eeb46b1dc1d13
https://pubmed.ncbi.nlm.nih.gov/10486435

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání